Prosecution Insights
Last updated: May 28, 2026
Application No. 17/502,842

PROCESSES AND KITS FOR IDENTIFYING ANEUPLOIDY

Non-Final OA §DOUBLEPATENT
Filed
Oct 15, 2021
Priority
Dec 22, 2009 — provisional 61/289,370 +3 more
Examiner
ZHANG, KAIJIANG
Art Unit
1684
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sequenom Inc.
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
525 granted / 686 resolved
+16.5% vs TC avg
Strong +35% interview lift
Without
With
+35.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
34 currently pending
Career history
713
Total Applications
across all art units

Statute-Specific Performance

§101
4.1%
-35.9% vs TC avg
§103
52.8%
+12.8% vs TC avg
§102
24.5%
-15.5% vs TC avg
§112
10.5%
-29.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 686 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application is being examined under the pre-AIA first to invent provisions. Election/Restrictions 2. Applicant’s election without traverse of Group I (claims 2-14) in the reply filed on 12/29/2025 is acknowledged. Applicant has canceled claims 15-19 of the non-elected Group II. 3. Claims 2-14 are currently pending and under examination. Double Patenting 4. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 5. Claims 2-14 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 11,180,799. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-16 of U.S. Patent No. 11,180,799 teach or render obvious all the steps and elements as recited in instant claims 2-14. Specifically, claim 1 of U.S. Patent No. 11,180,799 teaches a method that has all the steps and elements as required by instant claim 2 and is more specific with respect to the number of amplification primer pairs used. In addition, the features as recited in dependent claims 3-14 are also taught or rendered obvious by claims 1-16 of U.S. Patent No. 11,180,799. 6. Claims 2-14 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 9,926,593. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-16 of U.S. Patent No. 9,926,593 teach or render obvious all the steps and elements as recited in instant claims 2-14. Specifically, claim 1 of U.S. Patent No. 9,926,593 discloses a method that has all the steps and elements as required by instant claim 2 and is more specific. In addition, the features as recited in dependent claims 3-14 are also taught or rendered obvious by claims 1-16 of U.S. Patent No. 9,926,593. Conclusion 7. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAIJIANG ZHANG whose telephone number is (571)272-5207. The examiner can normally be reached Monday - Friday, 8:30 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached at 571-272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KAIJIANG ZHANG/Primary Examiner, Art Unit 1684
Read full office action

Prosecution Timeline

Oct 15, 2021
Application Filed
Feb 24, 2026
Non-Final Rejection mailed — §DOUBLEPATENT
May 19, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637671
GENETIC TOOLS FOR RECOMBINING TRANSGENES AT THE SAME LOCUS
3y 1m to grant Granted May 26, 2026
Patent 12624394
METHODS AND SYSTEMS FOR GENETIC ANALYSIS
10m to grant Granted May 12, 2026
Patent 12617815
BARCODED XTEN POLYPEPTIDES AND COMPOSITIONS THEREOF, AND METHODS FOR MAKING AND USING THE SAME
3y 11m to grant Granted May 05, 2026
Patent 12613244
Method for Rapid Accurate Dispensing, Visualization and Analysis of Single Cells
4y 8m to grant Granted Apr 28, 2026
Patent 12606814
OLIGONUCLEOTIDE PROBES AND USES THEREOF
4y 1m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+35.3%)
2y 8m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 686 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month